Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Neil Hounslow

Showing results (1-10 of 13) with videos related to

Pageof 2
Sort By:
Advances in Therapy|August 30, 2011
Comparative efficacy of pitavastatin and simvastatin in high-risk patients: a randomized controlled trialMats Eriksson, Dragos Budinski, Neil Hounslow
Clinical Drug Investigation|September 1, 2011
Comparison of the pharmacokinetics of pitavastatin by formulation and ethnic group: an open-label, single-dose, two-way crossover pharmacokinetic study in healthy Caucasian and Japanese menSteve Warrington, Shunji Nagakawa, Neil Hounslow
European Journal of Preventive Cardiology|February 21, 2012
Pitavastatin demonstrates long-term efficacy, safety and tolerability in elderly patients with primary hypercholesterolaemia or combined (mixed) dyslipidaemiaSteen Stender, Dragos Budinski, Neil Hounslow
Advances in Therapy|August 30, 2011
Long-term efficacy of pitavastatin versus simvastatinMats Eriksson, Dragos Budinski, Neil Hounslow
Clinical Pharmacology in Drug Development|April 29, 2016
Pitavastatin Concentrations Are Not Increased by CYP3A4 Inhibitor Itraconazole in Healthy SubjectsShunji Nakagawa, Masahiko Gosho, Yuji Inazu, et al.
Clinical and Translational Science|July 30, 2024
Drug-drug interactions between pemafibrate and statins on pharmacokinetics in healthy male volunteers: Open-label, randomized, 6-sequence, 3-period crossover studiesTomohiro Kamimura, Neil Hounslow, Hideki Suganami, et al.
International Journal of Clinical Pharmacology and Therapeutics|June 25, 2015
Pitavastatin therapy in polymedicated patients is associated with a low risk of drug-drug interactions: analysis of real-world and phase 3 clinical trial dataMasahiko Gosho, Masaya Tanahashi, Neil Hounslow, et al.
Atherosclerosis|January 19, 2010
Long-term treatment with pitavastatin is effective and well tolerated by patients with primary hypercholesterolemia or combined dyslipidemiaLeiv Ose, Dragos Budinski, Neil Hounslow, et al.
Current Medical Research and Opinion|September 30, 2009
Comparison of pitavastatin with simvastatin in primary hypercholesterolaemia or combined dyslipidaemiaLeiv Ose, Dragos Budinski, Neil Hounslow, et al.
European Journal of Preventive Cardiology|June 9, 2012
Pitavastatin shows greater lipid-lowering efficacy over 12 weeks than pravastatin in elderly patients with primary hypercholesterolaemia or combined (mixed) dyslipidaemiaSteen Stender, Dragos Budinski, Masahiko Gosho, et al.
Pageof 2

Showing results (1-10 of 13) with videos related to

Sort By:
Pageof 2
Advances in Therapy|August 30, 2011
Comparative efficacy of pitavastatin and simvastatin in high-risk patients: a randomized controlled trialMats Eriksson, Dragos Budinski, Neil Hounslow
Clinical Drug Investigation|September 1, 2011
Comparison of the pharmacokinetics of pitavastatin by formulation and ethnic group: an open-label, single-dose, two-way crossover pharmacokinetic study in healthy Caucasian and Japanese menSteve Warrington, Shunji Nagakawa, Neil Hounslow
European Journal of Preventive Cardiology|February 21, 2012
Pitavastatin demonstrates long-term efficacy, safety and tolerability in elderly patients with primary hypercholesterolaemia or combined (mixed) dyslipidaemiaSteen Stender, Dragos Budinski, Neil Hounslow
Advances in Therapy|August 30, 2011
Long-term efficacy of pitavastatin versus simvastatinMats Eriksson, Dragos Budinski, Neil Hounslow
Clinical Pharmacology in Drug Development|April 29, 2016
Pitavastatin Concentrations Are Not Increased by CYP3A4 Inhibitor Itraconazole in Healthy SubjectsShunji Nakagawa, Masahiko Gosho, Yuji Inazu, et al.
Clinical and Translational Science|July 30, 2024
Drug-drug interactions between pemafibrate and statins on pharmacokinetics in healthy male volunteers: Open-label, randomized, 6-sequence, 3-period crossover studiesTomohiro Kamimura, Neil Hounslow, Hideki Suganami, et al.
International Journal of Clinical Pharmacology and Therapeutics|June 25, 2015
Pitavastatin therapy in polymedicated patients is associated with a low risk of drug-drug interactions: analysis of real-world and phase 3 clinical trial dataMasahiko Gosho, Masaya Tanahashi, Neil Hounslow, et al.
Atherosclerosis|January 19, 2010
Long-term treatment with pitavastatin is effective and well tolerated by patients with primary hypercholesterolemia or combined dyslipidemiaLeiv Ose, Dragos Budinski, Neil Hounslow, et al.
Current Medical Research and Opinion|September 30, 2009
Comparison of pitavastatin with simvastatin in primary hypercholesterolaemia or combined dyslipidaemiaLeiv Ose, Dragos Budinski, Neil Hounslow, et al.
European Journal of Preventive Cardiology|June 9, 2012
Pitavastatin shows greater lipid-lowering efficacy over 12 weeks than pravastatin in elderly patients with primary hypercholesterolaemia or combined (mixed) dyslipidaemiaSteen Stender, Dragos Budinski, Masahiko Gosho, et al.
Pageof 2